His primary scientific interests are in Internal medicine, Endocrinology, Heart failure, Cardiology and Natriuretic peptide. His study in Atrial natriuretic peptide, Heart disease, Brain natriuretic peptide, Endothelin receptor and Renin–angiotensin system falls under the purview of Internal medicine. In his research on the topic of Endocrinology, NPR1 is strongly related with NPR2.
John C. Burnett studied Heart failure and Cardiac output that intersect with Pulmonary wedge pressure. His Cardiology study combines topics from a wide range of disciplines, such as Blood pressure, Diastole and Cohort. He interconnects Surgery, Peptide hormone, Neprilysin, Pharmacology and Peptide in the investigation of issues within Natriuretic peptide.
His scientific interests lie mostly in Internal medicine, Endocrinology, Heart failure, Cardiology and Natriuretic peptide. His study in Atrial natriuretic peptide, Kidney, Renal function, Brain natriuretic peptide and Receptor is done as part of Internal medicine. His research in Endocrinology focuses on subjects like Endothelin receptor, which are connected to Vasoconstriction.
His Heart failure research is multidisciplinary, incorporating perspectives in Neprilysin, Heart disease, Vasodilation and Intensive care medicine. His Cardiology study incorporates themes from Biomarker and Diastole. His study in Natriuretic peptide is interdisciplinary in nature, drawing from both Cyclic guanosine monophosphate, Pharmacology and Peptide.
Internal medicine, Natriuretic peptide, Endocrinology, Heart failure and Cardiology are his primary areas of study. His research in Internal medicine tackles topics such as Neprilysin which are related to areas like Sacubitril, Valsartan. Within one scientific family, John C. Burnett focuses on topics pertaining to Receptor under Natriuretic peptide, and may sometimes address concerns connected to Pharmacology, Signal transduction and Endogeny.
His biological study spans a wide range of topics, including NPR2 and NPR1. His Heart failure research includes elements of Fibrosis, Bioinformatics and Renal function. John C. Burnett focuses mostly in the field of Cardiology, narrowing it down to matters related to Cohort and, in some cases, Hazard ratio.
His scientific interests lie mostly in Internal medicine, Natriuretic peptide, Heart failure, Endocrinology and Cardiology. John C. Burnett regularly ties together related areas like Diabetes mellitus in his Internal medicine studies. His Natriuretic peptide study integrates concerns from other disciplines, such as Acute decompensated heart failure, Receptor, Activator, Pharmacology and Peptide.
His studies deal with areas such as Biomarker, Urinary system, Cohort and Bioinformatics as well as Heart failure. The Endocrinology study which covers Fibrosis that intersects with Hormone. His work deals with themes such as Prospective cohort study and Asymptomatic, which intersect with Cardiology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart Failure: The EVEREST Outcome Trial
Marvin A. Konstam;Mihai Gheorghiade;John C. Burnett;Liliana Grinfeld.
JAMA (2007)
Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis.
Amir Lerman;Brooks S. Edwards;John W. Hallett;Denise M. Heublein.
The New England Journal of Medicine (1991)
Atrial Natriuretic Peptide Elevation in Congestive Heart Failure in the Human
JC Burnett;PC Kao;DC Hu;DW Heser.
Science (1986)
The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy
Virginia V. Michels;Patricia P. Moll;Fletcher A. Miller;A. Jamil Tajik.
The New England Journal of Medicine (1992)
Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials.
Mihai Gheorghiade;Marvin A. Konstam;John C. Burnett;Liliana Grinfeld.
JAMA (2007)
Endothelin in human congestive heart failure.
Chi Ming Wei;Amir Lerman;Richard J. Rodeheffer;Christopher G.A. McGregor.
Circulation (1994)
Effects of synthetic atrial natriuretic factor on renal function and renin release
J. C. Burnett;J. P. Granger;T. J. Opgenorth.
American Journal of Physiology-renal Physiology (1984)
Consensus recommendations for the management of chronic heart failure: Introduction
Milton Packer;Jay N. Cohn;William T. Abraham;Wilson S. Colucci.
American Journal of Cardiology (1999)
Progression of left ventricular diastolic dysfunction and risk of heart failure.
Garvan C. Kane;Barry L. Karon;Douglas W. Mahoney;Margaret M. Redfield.
JAMA (2011)
Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor.
B S Edwards;R S Zimmerman;T R Schwab;D M Heublein.
Circulation Research (1988)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
Mayo Clinic
Mayo Clinic
Mayo Clinic
Mayo Clinic
Tufts Medical Center
Northwestern University
Tufts Medical Center
University of Pennsylvania
University of Gothenburg
Heart Care Foundation, ANMCO Research Center, Florence
Technion – Israel Institute of Technology
Carnegie Institution for Science
Utrecht University
University of Illinois at Urbana-Champaign
Grenoble Alpes University
University Medical Center Groningen
University of Copenhagen
Icahn School of Medicine at Mount Sinai
University of Washington
Ghent University
Max Planck Society
Institut Mérieux (France)
University of Maryland, College Park
University College London
University of California, Los Angeles
University of Michigan–Ann Arbor